Home » Cystic-Fibrosis Therapeutics Market
Cystic-Fibrosis Therapeutics Market
Published date: Feb 2022 •Formats:
Request Sample Schedule a Call

Global Cystic-Fibrosis Therapeutics Market By Drug Class (CFTR modulators, Mucolytic, Pancreatic enzyme supplements and Bronchodilators), By Route of Administration (Oral drugs and Inhaled drugs), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

  • Published date: Feb 2022
  • Report ID: 78573
  • Number of Pages: 245
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global Cystic Fibrosis Therapeutics Overview
      • 2.1. Cystic Fibrosis Therapeutics Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.2. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 3.2. Global Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 3.3. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 3.3.1. Global Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 3.3.3. CFTR modulators
        • 3.3.4. Mucolytics
        • 3.3.5. Pancreatic enzyme supplements
        • 3.3.6. Bronchodilators
      • 3.4. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 3.4.1. Global Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 3.4.3. Oral drugs
        • 3.4.4. Inhaled drugs
    • 4. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 4.2. North America Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 4.3. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 4.3.1. North America Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 4.3.3. CFTR modulators
        • 4.3.4. Mucolytics
        • 4.3.5. Pancreatic enzyme supplements
        • 4.3.6. Bronchodilators
      • 4.4. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 4.4.1. North America Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 4.4.3. Oral drugs
        • 4.4.4. Inhaled drugs
      • 4.5. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.5.1. North America Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.5.2.1. U.S.
          • 4.5.2.2. Canada
          • 4.5.2.3. Mexico
    • 5. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Europe Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 5.2. Europe Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 5.3. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 5.3.1. Europe Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 5.3.3. CFTR modulators
        • 5.3.4. Mucolytics
        • 5.3.5. Pancreatic enzyme supplements
        • 5.3.6. Bronchodilators
      • 5.4. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 5.4.1. Europe Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 5.4.3. Oral drugs
        • 5.4.4. Inhaled drugs
      • 5.5. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.5.1. Europe Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.5.2.1. U.K.
          • 5.5.2.2. Germany
          • 5.5.2.3. France
          • 5.5.2.4. Spain
          • 5.5.2.5. Italy
          • 5.5.2.6. Russia
          • 5.5.2.7. Rest of Europe
    • 6. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 6.2. Asia-Pacific Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 6.3. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 6.3.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 6.3.3. CFTR modulators
        • 6.3.4. Mucolytics
        • 6.3.5. Pancreatic enzyme supplements
        • 6.3.6. Bronchodilators
      • 6.4. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 6.4.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 6.4.3. Oral drugs
        • 6.4.4. Inhaled drugs
      • 6.5. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.5.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.5.2.1. China
          • 6.5.2.2. Japan
          • 6.5.2.3. South Korea
          • 6.5.2.4. India
          • 6.5.2.5. Rest of Asia-Pacific
    • 7. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. South America Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 7.2. South America Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 7.3. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 7.3.1. South America Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 7.3.3. CFTR modulators
        • 7.3.4. Mucolytics
        • 7.3.5. Pancreatic enzyme supplements
        • 7.3.6. Bronchodilators
      • 7.4. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 7.4.1. South America Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 7.4.3. Oral drugs
        • 7.4.4. Inhaled drugs
      • 7.5. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.5.1. South America Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.5.2.1. Brazil
          • 7.5.2.2. Argentina
          • 7.5.2.3. Rest of South America
    • 8. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 8.2. Middle East and Africa Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 8.3. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 8.3.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 8.3.3. CFTR modulators
        • 8.3.4. Mucolytics
        • 8.3.5. Pancreatic enzyme supplements
        • 8.3.6. Bronchodilators
      • 8.4. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 8.4.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 8.4.3. Oral drugs
        • 8.4.4. Inhaled drugs
      • 8.5. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.5.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.5.2.1. GCC
          • 8.5.2.2. Israel
          • 8.5.2.3. South Africa
          • 8.5.2.4. Rest of MEA
    • 9. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 9.1. Global Cystic Fibrosis Therapeutics Analysis by Region : Introduction
      • 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 9.2.1. North America
        • 9.2.2. Europe
        • 9.2.3. Asia-Pacific
        • 9.2.4. South America
        • 9.2.5. Middle East and Africa
    • 10. Global Cystic Fibrosis Therapeutics Competitive Landscape, Market Share Analysis, and Company Profiles
      • 10.1. Market Share Analysis
      • 10.2. Company Profiles
      • 10.3. Hoffmann-La Roche Ltd.
        • 10.3.1. Company Overview
        • 10.3.2. Financial Highlights
        • 10.3.3. Product Portfolio
        • 10.3.4. SWOT Analysis
        • 10.3.5. Key Strategies and Developments
      • 10.4. Gilead
        • 10.4.1. Company Overview
        • 10.4.2. Financial Highlights
        • 10.4.3. Product Portfolio
        • 10.4.4. SWOT Analysis
        • 10.4.5. Key Strategies and Developments
      • 10.5. Teva Pharmaceutical Industries Ltd.
        • 10.5.1. Company Overview
        • 10.5.2. Financial Highlights
        • 10.5.3. Product Portfolio
        • 10.5.4. SWOT Analysis
        • 10.5.5. Key Strategies and Developments
      • 10.6. Novartis AG
        • 10.6.1. Company Overview
        • 10.6.2. Financial Highlights
        • 10.6.3. Product Portfolio
        • 10.6.4. SWOT Analysis
        • 10.6.5. Key Strategies and Developments
      • 10.7. Vertex Pharmaceuticals Inc.
        • 10.7.1. Company Overview
        • 10.7.2. Financial Highlights
        • 10.7.3. Product Portfolio
        • 10.7.4. SWOT Analysis
        • 10.7.5. Key Strategies and Developments
      • 10.8. Alcresta Therapeutics
        • 10.8.1. Company Overview
        • 10.8.2. Financial Highlights
        • 10.8.3. Product Portfolio
        • 10.8.4. SWOT Analysis
        • 10.8.5. Key Strategies and Developments
      • 10.9. Merck & Co. Inc.
        • 10.9.1. Company Overview
        • 10.9.2. Financial Highlights
        • 10.9.3. Product Portfolio
        • 10.9.4. SWOT Analysis
        • 10.9.5. Key Strategies and Developments
      • 10.10. AIT (Advanced Inhalation Therapies)
        • 10.10.1. Company Overview
        • 10.10.2. Financial Highlights
        • 10.10.3. Product Portfolio
        • 10.10.4. SWOT Analysis
        • 10.10.5. Key Strategies and Developments
      • 10.11. Other Key Players
        • 10.11.1. Company Overview
        • 10.11.2. Financial Highlights
        • 10.11.3. Product Portfolio
        • 10.11.4. SWOT Analysis
        • 10.11.5. Key Strategies and Developments
    • 11. Assumptions and Acronyms
    • 12. Research Methodology
    • 13. Contact

     

    • List of Figures
      • Figure 1: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Class in 2022
      • Figure 2: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 3: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 4: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 5: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Region in 2022
      • Figure 6: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Region, 2016-2032
      • Figure 7: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 8: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Figure 9: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 10: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 11: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Figure 12: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 13: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 14: Global Cystic Fibrosis Therapeutics Market Share Comparison by Region (2016-2032)
      • Figure 15: Global Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 16: Global Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 17: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 18: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 19: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 20: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 21: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 22: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 23: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 24: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 25: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 26: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 27: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 28: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 29: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 30: North America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 31: North America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 32: North America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 33: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 34: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 35: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 36: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 37: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 38: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 39: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 40: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 41: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 42: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 43: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 44: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 45: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 46: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 47: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 48: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 49: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 50: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 51: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 52: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 53: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 54: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 55: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 56: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 57: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 58: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 59: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 60: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 61: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 62: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 63: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 64: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 65: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 66: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 67: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 68: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 69: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 70: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 71: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 72: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 73: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 74: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 75: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 76: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 77: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 78: South America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 79: South America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 80: South America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 81: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 82: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 83: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 84: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 85: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 86: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 87: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 88: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 89: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 90: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 91: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 92: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 93: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 94: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 95: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 96: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)

       

    • List of Tables
      • Table 1: Global Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 2: Global Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 3: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 4: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 5: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 6: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 7: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 8: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 9: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 10: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 11: Global Cystic Fibrosis Therapeutics Market Share Comparison by Region (2016-2032)
      • Table 12: Global Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 13: Global Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 14: North America Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 15: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 16: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 17: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 18: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 19: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 20: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 21: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 22: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 23: North America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 24: North America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 25: North America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 26: Europe Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 27: Europe Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 28: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 29: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 30: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 31: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 32: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 33: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 34: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 35: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 36: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 37: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 38: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 39: Asia-Pacific Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 40: Asia-Pacific Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 41: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 42: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 43: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 44: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 45: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 46: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 47: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 48: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 49: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 50: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 51: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 52: South America Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 53: South America Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 54: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 55: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 56: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 57: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 58: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 59: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 60: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 61: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 62: South America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 63: South America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 64: South America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 65: Middle East and Africa Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 66: Middle East and Africa Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 67: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 68: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 69: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 70: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 71: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 72: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 73: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 74: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 75: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 76: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 77: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
    • Hoffmann-La Roche Ltd.
    • GileadTeva Pharmaceutical Industries Ltd.
    • Novartis AG Company Profile
    • Vertex Pharmaceuticals Inc.
    • Alcresta Therapeutics
    • Merck & Co. Inc.
    • AIT (Advanced Inhalation Therapies)
    • Other Key Players
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Cystic-Fibrosis Therapeutics Market
  • 78573
  • Feb 2022
    • ★★★★★
      ★★★★★
    • (22)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore